AdCMV-p16

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug NameAdCMV-p16
Drug Alias Nameoncolytic adenovirus therapy expressing p16 INK4/CDKN2 (Theragen)
ClassificationBiologics > Oncolytic virus
Mechanisms of ActionImmunostimulants
TargetsUpdating
Therapy Area/IndicationsMusculoskeletal DiseasesColonic NeoplasmsColorectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesGermany
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesTheragen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTheragen Inc
Active IndicationsN/A
Inactive IndicationsMusculoskeletal DiseasesColonic NeoplasmsColorectal Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A